Friess Associates’s Medifast MED Stock Holding History

Friess Associates’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-21,000	Closed	-$3.36M	–	131
2018 Q2	$3.36M	Buy	+21,000	New	+$2.68M	0.27%	75

Other funds holding MED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Friess Associates's MED Position: Q3 2018 in Review

Friess Associates sold out of Medifast (MED) in Q3 2018, closing a stake of 21,000 shares — an estimated $3.36M sold.

Friess Associates first reported a position in MED in Q2 2018 and held it in 1 quarter. The position peaked at $3.36M in Q2 2018. 266 funds tracked by Wall St. Rank hold MED as of Q3 2018.

Friess Associates reported no remaining Medifast position as of Q3 2018 after selling out during the quarter.
Friess Associates sold 21,000 Medifast shares in Q3 2018, an estimated $3.36M.
Friess Associates first reported a position in Medifast in Q2 2018 and held it in 1 quarter.
Friess Associates's Medifast position peaked at $3.36M in Q2 2018.
266 funds tracked by Wall St. Rank held Medifast as of Q3 2018.

Based on Friess Associates's 13F filing for Q3 2018, filed 14 Nov 2018.